8-K: Biote Corp. Reports Solid Q1 2024 Results Driven by Procedure Revenue Growth and Improved Profitability

Biote Corp. announced a 4.4% increase in revenue to $46.8 million for the first quarter of 2024, driven by a 6.6% rise in procedure revenue and improved gross profit margins.

Summary

• Biote Corp. reported a revenue of $46.8 million for the first quarter of 2024, a 4.4% increase compared to the same period last year.
• Procedure revenue grew by 6.6% to $37.4 million, indicating stable demand from established clinics.
• The company's gross profit margin improved to 71.4%, a 240-basis point increase year-over-year.
• Biote experienced a net loss of $(5.8) million, a significant improvement from the $(21.4) million loss in the first quarter of 2023.
• Adjusted EBITDA increased by 8.0% to $14.2 million, with an adjusted EBITDA margin of 30.2%.
• The company reaffirmed its 2024 financial guidance, projecting revenue between $200 and $204 million and adjusted EBITDA between $60 and $63 million.
• Biote expects revenue growth to accelerate in the second half of 2024, driven by geographic expansion and enhanced practitioner relationships.
• The phased launch of BioteRx, a new suite of hormone and wellness therapies, is progressing well.
• The acquisition of Asteria Health, a manufacturer of compounded bioidentical hormones, was completed on March 18th and is being integrated into operations.

Sentiment

Score: 7

Explanation: The document shows positive financial results with improved profitability and reaffirmed guidance, but there are still some challenges and risks to consider. The sentiment is positive overall but not overly enthusiastic.

Positives

• Procedure revenue growth of 6.6% indicates strong demand for Biote's core services.
• The 240-basis point increase in gross profit margin to 71.4% demonstrates improved operational efficiency.
• The significant reduction in net loss from $(21.4) million to $(5.8) million shows a positive trend in profitability.
• Adjusted EBITDA growth of 8.0% and an increase in adjusted EBITDA margin to 30.2% highlight improved financial performance.
• The reaffirmation of 2024 financial guidance provides confidence in the company's future performance.
• The acquisition of Asteria Health is expected to strengthen Biote's competitive position and enable the development of innovative wellness therapies.
• The phased launch of BioteRx is progressing well, with positive responses from patients and practitioners.

Negatives

• The company still reported a net loss of $(5.8) million for the quarter.
• Dietary supplement revenue declined by 11.3% due to a distributor exiting the nutraceutical business.
• First half 2024 consolidated year-on-year revenue growth is expected to be in the low-single digits.

Risks

• The company faces competition in the hormone optimization and therapeutic wellness market.
• The success of new products like BioteRx is not guaranteed.
• The company's reliance on third parties for manufacturing bio-identical hormones poses a risk.
• Regulatory changes could impact the company's operations.
• The company's ability to expand into new markets and grow its business is subject to various factors.
• The integration of Asteria Health may present challenges.
• The company's financial performance could be affected by economic conditions and interest rate changes.

Future Outlook

Biote reaffirms its 2024 financial guidance, expecting revenue between $200 and $204 million and adjusted EBITDA between $60 and $63 million, with stronger revenue growth anticipated in the second half of the year.

Management Comments

• We are focused on driving accelerated revenue growth in the second half of 2024 by continuing to expand our geographic presence and strengthening our relationships with existing practitioners, said Terry Weber, Biote Chief Executive Officer.
• The phased launch of BioteRx, our new suite of hormone and evidence-based wellness therapies that launched in February, is progressing well, with both patients and practitioners responding favorably to our enhanced offerings, said Terry Weber, Biote Chief Executive Officer.
• We have begun to integrate Asteria Health into our operations, with a goal of achieving full vertical integration of our pellet manufacturing, said Terry Weber, Biote Chief Executive Officer.
• Based on our solid first quarter financial performance and our expectations for stronger revenue growth in the second half of the year, we reaffirm our 2024 financial guidance, concluded Ms. Weber.

Industry Context

Biote's focus on personalized hormone optimization and therapeutic wellness aligns with the growing trend of preventive healthcare and the increasing demand for personalized medicine. The acquisition of Asteria Health positions Biote to better control its supply chain and potentially develop new products, which is a competitive advantage in the industry.

Comparison to Industry Standards

• Biote's gross profit margin of 71.4% is strong compared to other healthcare companies, indicating efficient cost management.
• The company's adjusted EBITDA margin of 30.2% is also competitive, suggesting good operational profitability.
• Companies like CVS Health and Walgreens, while much larger, have lower gross profit margins, typically in the 20-30% range, highlighting Biote's focus on higher-margin services.
• Other companies in the wellness and hormone therapy space, such as SottoPelle and Defy Medical, are privately held, making direct financial comparisons difficult, but Biote's public reporting provides more transparency.
• Biote's growth in procedure revenue is a key indicator of its market penetration and acceptance of its treatment methods, which is a critical metric for companies in this sector.

Legal Proceedings

• Biote reached a definitive settlement in the litigation with Dr. Gary S. Donovitz, Biote's founder, which included the repurchase of 18.4 million shares and cancellation of 3.9 million unvested earnout shares.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and reaffirmed guidance.
• Practitioners will benefit from enhanced training programs and the expansion of BioteRx.
• Patients will benefit from the availability of new hormone and wellness therapies.
• Employees may benefit from the company's growth and improved financial stability.

Next Steps

• Biote plans to continue expanding BioteRx throughout its network.
• The company will continue to integrate Asteria Health into its operations.
• Biote will focus on driving accelerated revenue growth in the second half of 2024.
• The company will host a conference call to review the results and provide a business update.

Key Dates

Keywords

Biote, Hormone Optimization, Therapeutic Wellness, Procedure Revenue, Adjusted EBITDA, Gross Profit Margin, BioteRx, Asteria Health, Financial Results, Net Loss